Related references
Note: Only part of the references are listed.ABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium
Pooja Hingorani et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Continuous 14 Day Infusional Ifosfamide for Management of Soft-Tissue and Bone Sarcoma: A Single Centre Retrospective Cohort Analysis
Thomas J. Carter et al.
CANCERS (2020)
High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series
Emanuela Palmerini et al.
CELLS (2020)
Enhancing tumor T cell infiltration to enable cancer immunotherapy
Jin Zhang et al.
IMMUNOTHERAPY (2019)
Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod
Mariya Rozenblit et al.
SCIENTIFIC REPORTS (2019)
LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates
James W. Purcell et al.
CANCER RESEARCH (2018)
Targeting the tumour stroma to improve cancer therapy
Kenneth C. Valkenburg et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Immune oncology, immune responsiveness and the theory of everything
Tolga Turan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
LRRC15 is a novel antigen in sarcoma and the therapeutic target of the antibody-drug conjugate (ADC) ABBV-085
Eytan Ben-Ami et al.
CANCER RESEARCH (2018)
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
Alex F. Herrera et al.
BLOOD (2018)
Brentuximab vedotin: clinical updates and practical guidance
Jun Ho Yi et al.
BLOOD RESEARCH (2017)
Time-to-Event Analysis of Polatuzumab Vedotin-Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens
D. Lu et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
John M. Lambert et al.
ADVANCES IN THERAPY (2017)
Immunological hallmarks of stromal cells in the tumour microenvironment
Shannon J. Turley et al.
NATURE REVIEWS IMMUNOLOGY (2015)
CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2
D. Bedognetti et al.
BRITISH JOURNAL OF CANCER (2013)
Maturing antibody-drug conjugate pipeline hits 30
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2013)
An immune-active tumor microenvironment favors clinical response to ipilimumab
Rui-Ru Ji et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
Kenneth P. Olive et al.
SCIENCE (2009)
Phase III trial of two Investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study
Paul Lorigan et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
KJ Hamblett et al.
CLINICAL CANCER RESEARCH (2004)
Share Paper
